KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
Biocon Biologics to launch Trastuzumab, Nivolumab, Pembrolizumab biosimilars for cancer. Expanding oncology portfolio.
GlobalData on MSN
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...
US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while ...
Biocon Biologics plans to launch three new oncology biosimilars, aiming to strengthen its cancer treatment portfolio and provide cost-effective alternatives.
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
Ontario becomes the first province to list the combination under the new FAST pilot program, supporting timely access for eligible patients "For thousands of Ontarians facing a cancer diagnosis, fast ...
BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...
The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going ...
The court directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback